Jurriaan Dekkers Sells 4,000 Shares of Faron Pharmaceuticals Oy (LON:FARN) Stock

Faron Pharmaceuticals Oy (LON:FARN) insider Jurriaan Dekkers sold 4,000 shares of the firm’s stock in a transaction dated Monday, January 12th. The shares were sold at an average price of GBX 182, for a total value of £7,280.

Faron Pharmaceuticals Oy Stock Performance

Shares of Faron Pharmaceuticals Oy stock traded down GBX 5 on Tuesday, reaching GBX 180. The stock had a trading volume of 894 shares, compared to its average volume of 10,138. The company has a debt-to-equity ratio of 922.55, a quick ratio of 1.09 and a current ratio of 1.45. The business’s 50-day moving average price is GBX 184.03 and its two-hundred day moving average price is GBX 192.60. The stock has a market cap of £205.96 million, a P/E ratio of -6.67 and a beta of 0.36. Faron Pharmaceuticals Oy has a fifty-two week low of GBX 146 and a fifty-two week high of GBX 270.

Faron Pharmaceuticals Oy Company Profile

Faron (AIM: FARN, First North: FARON) is a clinical stage biopharmaceutical company developing novel treatments for medical conditions with significant unmet needs. The Company currently has a pipeline based on the receptors involved in regulation of immune response in oncology and organ damage. Clevegen (bexmarilimab), its investigative precision immunotherapy, is a novel anti-Clever-1 antibody with the ability to switch immune suppression to immune activation in various conditions, with potential across oncology, infectious disease and vaccine development.